Arterial stiffness as a model to dissect chronic inflammation in FMF

Kukuy, Olga; Leiba, Adi; Mendel, Liran; Benor, Ariel; Giat, Eitan; Perski, Oleg; Feld, Olga; Kessel, Y; Zvi, I Ben; Lidar, Merav; Livneh, Avi

doi:10.1186/1546-0096-13-s1-p93

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have demonstrated that they had PWV values similar to healthy controls, suggesting a favorable outcome of intermittent, waxing and waning inflammation, as opposed to chronic, low-grade, inflammation. We also suggested that colchicine could have a protective role on arterial structure and function [16].…”

Section: Discussionmentioning

confidence: 84%

Patients with CKD Secondary to Glomerular Disorders have Lower Arterial Stiffness, as Compared to Hypertensive and Diabetic CKD

Lencovsky,

Angel-Korman,

Glasswine

et al. 2023

Artery Res

View full text Add to dashboard Cite

Background Chronic kidney disease (CKD) manifested as reduced GFR and/or albuminuria, has been known to accelerate arterial stiffness and early vascular aging (EVA). Diabetes, hypertension, and glomerular disorders are the leading causes of CKD and renal failure. The question which etiology contributes more to this vascular phenomenon-hypertensive and diabetic CKD or CKD secondary to immune-mediated glomerulonephritis—remained unclear. Objective To compare pulse wave velocity (PWV), a marker of arterial stiffness, between CKD patients of different etiologies: hypertensive and diabetic nephrosclerosis. vs. CKD secondary to glomerular disorders. Methods Clinical data were collected on 56 patients followed at the Nephrology and Hypertension Institute in Samson Assuta Ashdod University Hospital. All patients had at least one visit at our Nephrology clinics prior to recruitment. All patients with a glomerular disorder had a clinical-pathological diagnosis based on a recent kidney biopsy. Pulse wave velocity (PWV) was measured using a validated Sphygmocor XCEL® device. Univariate and multivariate analyses were performed to compare PWV between hypertensive/diabetic CKD and CKD secondary to glomerular disorders. Results PWV was significantly higher in the hypertensive/diabetic CKD group, compared to the CKD-GN group, with an average of. 12.2 m/s vs 8.3 m/s, respectively (p < 0.001). In a multivariate linear regression model, having CKD secondary to glomerulonephritis was associated with a significantly lower PWV (B = − 3.262, p < 0.001), compared with CKD secondary to hypertension and diabetes, with adjustment of age, creatinine, and comorbidities. Conclusion CKD Patients secondary to glomerulonephritis, have lower PWV when compared to CKD patients with diabetes and/or hypertension, even after adjusting for age, renal function, and the presence of comorbidities. It is intriguing to further study the possible protective role of immunosuppression on the arterial properties of CKD patients.

show abstract

Section: Discussionmentioning

confidence: 84%

Patients with CKD Secondary to Glomerular Disorders have Lower Arterial Stiffness, as Compared to Hypertensive and Diabetic CKD

Lencovsky,

Angel-Korman,

Glasswine

et al. 2023

Artery Res

View full text Add to dashboard Cite

show abstract

“…The duration of treatment with colchicine is inversely correlated with the grade of arterial stiffness, even in the pediatric age range. 72,73 Besides patients with FMF, colchicine confers cardiovascular protection to patients with coronary artery disease. The low-dose colchicine is a prospective randomized clinical trial conducted in 532 patients with stable coronary disease.…”

Section: Colchicine Reduces Cardiovascular Riskmentioning

confidence: 99%

“…Microtubule-targeting agents improve vascular disease and reduce cardiovascular risk, although their therapeutic use in clinical practice remains undefined. 72,73 The pathophysiological mechanisms underlying cardiovascular protection associated with microtubule-targeting agents are uncertain (Fig. 3).…”

Section: Potential Mechanisms By Which Microtubule-targeting Agents M...mentioning

confidence: 99%

“…28 Collagen gel-based scaffolds lined with vascular smooth muscle cells may improve vascular tissue assembly in vitro. 16 There is compelling evidence from clinical studies that target of rapamycin (TOR) inhibitors (sirolimus and everolimus), [29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47] cilostazol (a drug that elevates intracellular cyclic adenosine monophosphate (cAMP) concentration), and microtubule-destabilizing agents (colchicine) [72][73][74][75][76][77][78][79][80][81][82] improve vascular disease and confer cardiovascular protection, although their indications in the clinical field remain to be established. The mechanisms by which these agents improve vascular function are not fully understood, but they may converge with the actin cytoskeleton and its putative impact on ECM synthesis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular protection associated with cilostazol, colchicine and target of rapamycin inhibitors

Adeva‐Andany

Fernández‐Fernández

Carneiro-Freire

et al. 2022

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

:An alteration in extracellular matrix (ECM) production by vascular smooth muscle cells is a crucial event in the pathogenesis of vascular diseases such as aging-related, atherosclerosis and allograft vasculopathy. The human target of rapamycin (TOR) is involved in the synthesis of ECM by vascular smooth muscle cells. TOR inhibitors reduce arterial stiffness, blood pressure, and left ventricle hypertrophy and decrease cardiovascular risk in kidney graft recipients and patients with coronary artery disease and heart allograft vasculopathy. Other drugs that modulate ECM production such as cilostazol and colchicine have also demonstrated a beneficial cardiovascular effect. Clinical studies have consistently shown that cilostazol confers cardiovascular protection in peripheral vascular disease, coronary artery disease, and cerebrovascular disease. In patients with type 2 diabetes, cilostazol prevents the progression of subclinical coronary atherosclerosis. Colchicine reduces arterial stiffness in patients with familial Mediterranean fever and patients with coronary artery disease. Pathophysiological mechanisms underlying the cardioprotective effect of these drugs may be related to interactions between the cytoskeleton, TOR signaling, and cyclic adenosine monophosphate (cAMP) synthesis that remain to be fully elucidated. Adult vascular smooth muscle cells exhibit a contractile phenotype and produce little ECM. Conditions that upregulate ECM synthesis induce a phenotypic switch toward a synthetic phenotype. TOR inhibition with rapamycin reduces ECM production by promoting the change to the contractile phenotype. Cilostazol increases the cytosolic level of cAMP, which in turn leads to a reduction in ECM synthesis. Colchicine is a microtubule-destabilizing agent that may enhance the synthesis of cAMP.

show abstract

Arterial stiffness as a model to dissect chronic inflammation in FMF

Cited by 2 publications

References 0 publications

Patients with CKD Secondary to Glomerular Disorders have Lower Arterial Stiffness, as Compared to Hypertensive and Diabetic CKD

Patients with CKD Secondary to Glomerular Disorders have Lower Arterial Stiffness, as Compared to Hypertensive and Diabetic CKD

Cardiovascular protection associated with cilostazol, colchicine and target of rapamycin inhibitors

Contact Info

Product

Resources

About